Predictors for short bowel syndrome in Crohn's disease
- PMID: 32938546
- DOI: 10.1016/j.dld.2020.08.029
Predictors for short bowel syndrome in Crohn's disease
Abstract
Background and aim: Patients with Crohn's disease (CD) are at risk for short bowel syndrome (SBS). We investigated independent predictors for SBS in these patients to allow the development of preventive strategies.
Methods: All adult patients seen at the Nancy University hospital for CD or SBS between 2012 and 2019 were eligible for inclusion in this case-control study. Each CD patient with SBS was matched to 9 controls.
Results: 410 CD patients were included (369 without SBS and 41 with SBS). Subjects with SBS underwent significantly more bowel resections (median value of 3 vs 1, p<0.0001) and median time before the first surgery was not different than controls (6 vs 4 years, p=0.59). A higher need for parenteral support was found in end-jejunostomy SBS than in jejunocolic and jejunoileal SBS (70.6% vs 25% and 0%, p=0.0031). Montreal B1 behavior (OR 0.02, CI 95% 0-0.08) and budesonide treated-patients (OR=0.03, CI 95% 0.003-0.2) were at lower risk of SBS, while IV steroid treated-patients were at higher risk (OR=8.5, CI 95% 3.0-24.9).
Conclusion: Montreal B1 behavior, IV steroids and budesonide use are influencing predictors for this complication. These predictors should be assessed in daily clinical practice to prevent SBS occurrence.
Keywords: Crohn's disease; Inflammatory bowel diseases; Risk factors; Short bowel syndrome; Surgery.
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest S. Vaillant declares no conflict of interest. L. Guillo declares no conflict of interest. N. Michot declares no conflict of interest. F. D'Amico declares no conflict of interest. A. Germain declares no conflict of interest. S. Danese has served as a speaker, consultant and advisory board member for Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance. C. Baumann declares no conflict of interest. H. Rousseau declares no conflict of interest. D. Quilliot as a speaker and consultant and advisory board member for Baxter, Aguettant, Shire, Fresenius-Kabi, Mayoly-Spindler, Johnson & Johnson Medical, Ethicon, Celgene. L. Peyrin-Biroulet has served as a speaker, consultant and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC- Pharma, Index Pharmaceuticals, Amgen, Sandoz, For- ward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, Theravance.
Similar articles
-
Risk factors for short bowel syndrome in patients with Crohn's disease.Surg Today. 2012 May;42(5):447-52. doi: 10.1007/s00595-011-0098-0. Epub 2011 Dec 17. Surg Today. 2012. PMID: 22173650
-
Clinical outcomes in Crohn's disease patients with short bowel syndrome on home parenteral nutrition are comparable to those with short bowel syndrome from other etiologies.Clin Nutr. 2025 Jun;49:149-156. doi: 10.1016/j.clnu.2025.04.015. Epub 2025 Apr 24. Clin Nutr. 2025. PMID: 40305998
-
Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome.Clin Gastroenterol Hepatol. 2017 Dec;15(12):1908-1914.e2. doi: 10.1016/j.cgh.2017.06.040. Epub 2017 Jun 27. Clin Gastroenterol Hepatol. 2017. PMID: 28666947
-
Inflammatory Bowel Disease and Short Bowel Syndrome.Surg Clin North Am. 2019 Dec;99(6):1209-1221. doi: 10.1016/j.suc.2019.08.010. Epub 2019 Sep 23. Surg Clin North Am. 2019. PMID: 31676059 Review.
-
Parenteral nutrition: a life-saving intervention for 4 months in short bowel syndrome-a case report and review of the literature.J Med Case Rep. 2024 Mar 21;18(1):122. doi: 10.1186/s13256-024-04442-1. J Med Case Rep. 2024. PMID: 38509559 Free PMC article. Review.
Cited by
-
Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure.World J Gastroenterol. 2022 Nov 28;28(44):6258-6270. doi: 10.3748/wjg.v28.i44.6258. World J Gastroenterol. 2022. PMID: 36504557 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical